Human medicines European public assessment report (EPAR): Yuvanci, macitentan,tadalafil, Date of authorisation: 27/09/2024, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Vazkepa, icosapent ethyl, Date of authorisation: 26/03/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Lyxumia, lixisenatide, Date of authorisation: 31/01/2013, Revision: 21, Status: Withdrawn

Human medicines European public assessment report (EPAR): Yuflyma, adalimumab, Date of authorisation: 11/02/2021, Revision: 20, Status: Authorised

Committee for Advanced Therapies (CAT): 3-5 December 2025, European Medicines Agency, Amsterdam, the Netherlands, from 3 December 2025 to 5 December 2025

Applications for new human medicines under evaluation: February 2026

Third European Medicines Agency (EMA) and IPFA - PPTA global bilateral meeting, European Medicines Agency, Amsterdam, the Netherlands, 9 February 2026

List of medicines currently in PRIME scheme

Human medicines European public assessment report (EPAR): DuoTrav, travoprost,timolol, Date of authorisation: 23/04/2006, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Avzivi, bevacizumab, Date of authorisation: 26/07/2024, Revision: 2, Status: Authorised